CXCR2-siRNA重组质粒治疗宫颈癌的动物实验

发布时间：2018-04-20 10:09

本文选题：siRNA + CXCR　；参考：《中国老年学杂志》2015年11期

【摘要】：目的研究趋化因子受体CXCR2的siRNA质粒构建及对裸鼠移植宫颈癌的抑制作用。方法将通过人源CXCR2的基因序列设计的siRNA和质粒p DC316-EGFP-U6通过内切酶链接,同时引入胆固醇修饰,将重组质粒免疫建立好的裸鼠模式动物,通过测算评价重组质粒的治疗效果。结果琼脂糖凝胶电泳发现重组质粒大小正确,浓度合适;经过28 d的治疗,空白对照组和空质粒对照组肿瘤体积生长比较无差异(P0.05);重组质粒治疗组的效果明显,与前两组比较差异显著(P0.01),并且重组质粒治疗组的抑瘤率达到50%;荧光显微镜观察增强绿色荧光信号,产生荧光的细胞约占总细胞的8%,体内转染效果明显。结论经过本实验设计和构建的重组质粒对趋化因子受体的表达具有抑制作用,在裸鼠模式动物治疗效果中具有重要意义。
[Abstract]:Objective to study the construction of siRNA plasmid of chemokine receptor CXCR2 and its inhibitory effect on cervical cancer transplantation in nude mice. Methods the recombinant plasmid siRNA and plasmid p DC316-EGFP-U6 designed by human CXCR2 gene sequence were linked by endonuclease and cholesterol modified. The recombinant plasmid was immunized with nude mice model animal. The therapeutic effect of recombinant plasmid was evaluated by measuring and evaluating the therapeutic effect of recombinant plasmid. Results agarose gel electrophoresis showed that the size of recombinant plasmid was correct and the concentration was suitable. After 28 days of treatment, there was no difference in tumor volume growth between blank control group and blank plasmid control group, and the effect of recombinant plasmid treatment group was obvious. Compared with the former two groups, there was a significant difference between the two groups, and the inhibition rate of the recombinant plasmid treatment group reached 50. The fluorescence microscope observed enhanced green fluorescence signal, the fluorescent cells produced fluorescence accounted for about 8 of the total cells, and the transfection effect in vivo was obvious. Conclusion the recombinant plasmid designed and constructed in this study can inhibit the expression of chemokine receptor and play an important role in the treatment of nude mice.
【作者单位】：中国医科大学附属盛京医院超声科;中国医科大学附属盛京医院急诊科;温州医科大学附属第二医院外科;
【分类号】：R737.33

【参考文献】